Liu Li
Infectious disease department, Hunan provincial peoples ~ hospital (The first affiliated hospital of Hunan Normal university), Hunan province, Changsha, 410000 China.
Infect Agent Cancer. 2020 Feb 4;15:8. doi: 10.1186/s13027-020-0277-y. eCollection 2020.
The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy. To have a better understanding of HCC with HBV, we compared the clinical features of patients with HCC receiving or not receiving NUC therapy.
We retrospectively reviewed the medical records of 76 patients with HBV-caused HCC who received treatment at the Hunan Provincial Peoples' Hospital starting from January 1, 2008 to December 31, 2017. They were categorized into two groups, namely, NUC group and non-NUC group, based on whether they had received NUC therapy or not.
The percentage of liver pain (36.36% vs. 79.07%; < 0.05) and appetite loss (30.30% vs. 70.27%; < 0.05) in the NUC group was lower than that in the non-NUC group. We observed a similar trend for the percentage of undetectable HBV-DNA (11.63% vs. 63.64%; < 0.05) and normal ALT (25.58% vs. 75.76%; < 0.05) between non-NUC and NUC groups. There were no significant differences between the two groups with respect to TBiL ( = 0.370) and ALB ( = 0.475). The same trend was observed for the proportion of HBeAg negative ( = 0.719) and AFP ≤ 14.65 ng/mL ( = 0.199) in both groups. Single tumor nodule was more common in the NUC group compared to the non-NUC group (66.67% vs. 6.98%; < 0.05). An opposite trend was observed for portal vein invasion (18.18% vs. 79.07%; < 0.05) and metastasis (0% vs. 44.19%; < 0.05).
Nucleos(t) ide analog therapy exerts a significant impact on the clinical and radiological characteristics of hepatocellular carcinoma with HBV. Patients receiving nucleos(t) ide analog therapy were found to have milder symptoms and fewer radiographic findings.
接受或未接受核苷（酸）类似物（NUC）治疗的乙型肝炎病毒（HBV）相关肝细胞癌（HCC）患者的临床表现差异显著。为了更好地了解HBV相关HCC，我们比较了接受或未接受NUC治疗的HCC患者的临床特征。
我们回顾性分析了2008年1月1日至2017年12月31日在湖南省人民医院接受治疗的76例HBV相关HCC患者的病历。根据是否接受过NUC治疗，将他们分为两组，即NUC组和非NUC组。
NUC组肝区疼痛（36.36%对79.07%；P<0.05）和食欲减退（30.30%对70.27%；P<0.05）的发生率低于非NUC组。非NUC组和NUC组在HBV-DNA检测不到（11.63%对63.64%；P<0.05）和ALT正常（25.58%对75.76%；P<0.05）的发生率方面也观察到类似趋势。两组在总胆红素（P=0.370）和白蛋白（P=0.475）方面无显著差异。两组在HBeAg阴性（P=0.719）和甲胎蛋白≤14.65 ng/mL（P=0.199）的比例方面也观察到相同趋势。与非NUC组相比，NUC组单肿瘤结节更常见（66.67%对6.98%；P<0.05）。门静脉侵犯（18.18%对79.07%；P<0.05）和转移（0%对44.19%；P<0.05）则观察到相反趋势。
核苷（酸）类似物治疗对HBV相关肝细胞癌的临床和影像学特征有显著影响。接受核苷（酸）类似物治疗的患者症状较轻，影像学表现较少。
